insights_auto
Why is 22UA down 6.35%?
Dive Deeperchevron_right
22UA:ETR
BioNTech SE - ADR
€81.10
arrow_downward
-6.35%(-5.50) 1D
Oct 13, 5:35:39 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€86.15
High
€86.20
Low
€79.70
Mkt. cap
22.36B
Avg. vol.
24.78K
Volume
76.11K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€86.15
High
€86.20
Low
€79.70
Mkt. cap
22.36B
Avg. vol.
24.78K
Volume
76.11K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance
·
2 hours ago
What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?
TipRanks
·
2 hours ago
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
TradingKey
·
3 hours ago
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
ad-hoc-news.de
·
4 hours ago
BioNTech's BNT113 Hangs on Overall Survival as Shares Retreat
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR